ReShape Lifesciences (RSLS) Stock Statistics & Valuation Metrics

ReShape Lifesciences has a market cap or net worth of $6.39M. The enterprise value is $3.43M.

ReShape Lifesciences has 11.28M shares outstanding. The number of shares has decreased by -2.65% in one year.

ReShape Lifesciences’s return on equity (ROE) is -1.71 and return on invested capital (ROIC) is -210.18%.

The current PE Ratio of ReShape Lifesciences is -0.13. ReShape Lifesciences’s PEG ratio is <0.01.

In the last 12 months, ReShape Lifesciences had revenue of $8.18M and earned -$7.07M in profits. Earnings per share was -$16.40.

In the last 12 months, operating cash flow was -$6.20M and capital expenditures $0.00, giving a free cash flow of -$6.20M billion.

ReShape Lifesciences pays an annual dividend of , resulting in a dividend yield of

ReShape Lifesciences upcoming earnings date is May 20, 2025, Before Open.

ReShape Lifesciences as a current ratio of 2.73, with Debt / Equity ratio of 0.04

In the past 12 months, ReShape Lifesciences has paid $66.00K in taxes.

ReShape Lifesciences EV to EBITDA ratio is 0.19, with an EV/FCF ratio of 0.16.

ReShape Lifesciences has $743.00K in cash and marketable securities with $191.00K in debt, giving a net cash position of -$552.00K billion.

Gross margin is 63.93%, with operating margin of -168.69%, and net profit margin of -131.22%.

The average price target for ReShape Lifesciences is , which is 11.43% higher than the current price. The consensus rating is